Abstract: This invention relates to molecular catalysts and chemical reactions utilizing the same, and particularly to molecular catalysts for efficient catalytic oxidation of hydrocarbons, such as hydrocarbons from natural gas. The molecular catalytic platform provided herein is capable of the facile oxidation of hydrocarbons, for example, under ambient conditions such as near room temperature and atmospheric pressure.

Abstract: A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.

Abstract: A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.

Abstract: The present invention provides a catalyst composition and process for preparing olefin polymers. The catalyst composition includes a metallocene catalyst or a single-site catalyst, a mesoporous molecular sieve, and an aluminum-containing cocatalyst such as MAO. The cocatalyst is present in an amount such that the molar ratio of aluminum content in cocatalyst to the metal content in metallocene is from 0 to 200. When the catalyst composition is used for preparing polyolefins, the MAO amount can be decreased; thus, the production costs are greatly reduced.

Abstract: The present invention provides a metallocene catalyst supported on a molecular seive having “tubules-within-a-tubule” morphology. When the metallocene catalyst is used for preparing polyolefin, the MAO amount can be decreased to an amount such that the molar ratio of Al/Zr is below 200. Thus, production costs are greatly reduced.

Abstract: The present invention relates to a method for synthesizing mesoporous aluminosilicate or pure-silica molecular sieves with newly hierarchical morphologies by adding suitable amount of alcohol. There are hollow sphere, hollow sphere with a pillar in it and solid sphere by adjusting the Al2O3/SiO2 and tetraethylorthosilicate/SiO2 ratio. The wall of the micron-sized spherical structure consisted of well-ordered cylindrical pores of nanometer size. The dimensions and the morphologies of the mesoporous structure are adjustable by varying the reaction components as the water content, the silicon/surfactant ratio and the reaction and the hydrothermal temperature.

Abstract: The present invention relates to a method for synthesizing mesoporous aluminosilicate and pure silica molecular sieves of new micro-tubular morphology. The wall of the microtubules contains coaxial cylindrical pores of nanometer size. The diameter of the hollow tubular is adjustable from 0.1 to 3 micrometer by varying the reaction conditions such as the surfactant/water ratio, the addition of salts or cosurfactants, the surfactants with different carbon chain length and the silicon/aluminum ratio.

Abstract: An echo contrast agent for use in echocardiography is disclosed which can be introduced into the body through peripheral venous injection to opacify left ventricle. The echo agent to be injected into the body contains a plurality of gas-in-liquid microbubbles which are smaller than red blood cells and can therefore traverse the pulmonary circulation to reach the left ventricle in substantial quantity to effectuate opacification thereof. The echo contrast agent disclosed in this invention contains: (a) an aqueous solution containing 0.40-0.60 grams of albumin and 4.0-10.0 grams of glucose per 10 ml solution mixed with (b) glycerin. The ratio between (b) and (a) should be no less than 0.050. A method for preparing this echo contrast agent was also disclosed.

Abstract: An echo contrast agent for use in echocardiography is disclosed which can be introduced into the body through peripheral venous injection to opacify left ventricle. The echo agent to be injected into the body contains a plurality of gas-in-liquid microbubbles which are smaller than red blood cells and can therefore traverse the pulmonary circulation to reach the left ventricle in substantial quantity to effectuate opacification thereof. The echo contrast agent disclosed in this invention contains: (a) an aqueous solution containing 0.40-0.60 grams of albumin and 4.0-10.0 grams of glucose per 10 ml solution mixed with (b) glycerin. The ratio between (b) and (a) should be no less than 0.050. A method for preparing this echo contrast agent was also disclosed.